TTH - hopefully we will hear from DECA on this subject soon.
However, based on my discussions with Domain Capital, and also with Allen Bollands, it is not just the fact that GBI's test is capable of genotyping that makes it attractive.
In order to be a commercially successful proposition the GBI test (PapType) needs to be cheap to manufacture for GBI (as the selling price of HPV tests needs to be sub $20 in order to be truly competitive)and also be CHEAP for the path labs to run. . . .as the cheaper it is for the path lab to run the test, the better their margin.
It is in these areas that the GBI test stacks up well against all of the competition currently in the market AND it is these factors that motivated Sonic to get involved in assisting with bringing the test to market in the USA.
I don't know anything much about the PLT test - but if it stacked up well as a commercial proposition on a standalone basis then i reckon PLT would have made more of a song and dance about it thus far. Therefore, my hunch is that while it might be successful in genotyping HPV, there might be other cost-related reasons why it is yet to find a commercial market.
GBI Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
